Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Cysteine specific targeting of the functionally distinct peroxiredoxin and glutaredoxin proteins by the investigational disulfide BNP7787.

Parker AR, Petluru PN, Nienaber VL, Badger J, Leverett BD, Jair K, Sridhar V, Logan C, Ayala PY, Kochat H, Hausheer FH.

Molecules. 2015 Mar 18;20(3):4928-50. doi: 10.3390/molecules20034928.

2.

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.

Parker AR, Petluru PN, Nienaber VL, Zhao M, Ayala PY, Badger J, Chie-Leon B, Sridhar V, Logan C, Kochat H, Hausheer FH.

Onco Targets Ther. 2015 Feb 4;8:375-83. doi: 10.2147/OTT.S73690. eCollection 2015.

3.

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K, Watanabe T, Hausheer FH.

Support Care Cancer. 2012 Dec;20(12):3355-64. doi: 10.1007/s00520-012-1492-x. Epub 2012 May 15.

PMID:
22584733
4.

Accumulation of BNP7787 in human renal proximal tubule cells.

Hausheer FH, Ding D, Shanmugarajah D, Leverett BD, Huang Q, Chen X, Kochat H, Ayala PY, Petluru PN, Parker AR.

J Pharm Sci. 2011 Sep;100(9):3977-84. doi: 10.1002/jps.22510. Epub 2011 Feb 22.

PMID:
21344411
5.

BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro.

Parker AR, Petluru PN, Wu M, Zhao M, Kochat H, Hausheer FH.

Mol Cancer Ther. 2010 Sep;9(9):2558-67. doi: 10.1158/1535-7163.MCT-10-0300. Epub 2010 Aug 31.

6.

Assessment of cancer-related neuropathy and neuropathic pain.

Cleeland CS, Farrar JT, Hausheer FH.

Oncologist. 2010;15 Suppl 2:13-8. doi: 10.1634/theoncologist.2009-S501. Review.

7.

Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain.

Lema MJ, Foley KM, Hausheer FH.

Oncologist. 2010;15 Suppl 2:3-8. doi: 10.1634/theoncologist.2009-S505. Review.

8.

Cancer neuropathic pain: overview of current status and future objectives.

Hausheer FH, Foley KM.

Oncologist. 2010;15 Suppl 2:1-2. doi: 10.1634/theoncologist.2009-S506. No abstract available.

9.

Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N.

Hausheer FH, Parker AR, Petluru PN, Jair KW, Chen S, Huang Q, Chen X, Ayala PY, Shanmugarajah D, Kochat H.

Cancer Chemother Pharmacol. 2011 Feb;67(2):381-91. doi: 10.1007/s00280-010-1333-x. Epub 2010 May 4.

PMID:
20440617
10.

Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.

Hausheer FH, Shanmugarajah D, Leverett BD, Chen X, Huang Q, Kochat H, Petluru PN, Parker AR.

Cancer Chemother Pharmacol. 2010 Apr;65(5):941-51. doi: 10.1007/s00280-009-1101-y. Epub 2009 Aug 28.

PMID:
19714332
11.

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH.

Support Care Cancer. 2009 Dec;17(12):1483-91. doi: 10.1007/s00520-009-0613-7. Epub 2009 Mar 28.

PMID:
19330359
12.

Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography.

Shanmugarajah D, Ding D, Huang Q, Chen X, Kochat H, Petluru PN, Ayala PY, Parker AR, Hausheer FH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 1;877(10):857-66. doi: 10.1016/j.jchromb.2009.02.056. Epub 2009 Feb 28.

PMID:
19278906
13.

Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).

Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH.

Support Care Cancer. 2009 Aug;17(8):1071-80. doi: 10.1007/s00520-008-0550-x. Epub 2008 Dec 17.

PMID:
19089463
14.

A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Kuroi K, Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Watanabe T, Bain S, Hausheer FH.

Jpn J Clin Oncol. 2008 Nov;38(11):748-54. doi: 10.1093/jjco/hyn100. Epub 2008 Oct 8.

PMID:
18845520
15.

Stereoselectivity in Diels-Alder reactions of diene-substituted N-alkoxycarbonyl-1,2-dihydropyridines.

Krow GR, Huang Q, Szczepanski SW, Hausheer FH, Carroll PJ.

J Org Chem. 2007 Apr 27;72(9):3458-66. Epub 2007 Mar 30.

PMID:
17394357
16.

Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.

Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F.

Semin Oncol. 2006 Feb;33(1):15-49. Review.

PMID:
16473643
17.

Effect of Synthetic Truncated Apolipoprotein C-I Peptide on Plasma Lipoprotein Cholesterol in Nonhuman Primates.

Kushwaha RS, McGill HC Jr, Hausheer FH.

J Biomed Biotechnol. 2004;2004(4):177-184.

18.

Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.

Verschraagen M, Boven E, Torun E, Hausheer FH, Bast A, van der Vijgh WJ.

Biochem Pharmacol. 2004 Aug 1;68(3):493-502.

PMID:
15242815
19.

Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.

Verschraagen M, Boven E, Torun E, Erkelens CA, Hausheer FH, van der Vijgh WJ.

Br J Cancer. 2004 Apr 19;90(8):1654-9.

20.
21.

Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.

Verschraagen M, Boven E, Ruijter R, van der Born K, Berkhof J, Hausheer FH, van der Vijgh WJ.

Clin Pharmacol Ther. 2003 Aug;74(2):157-69.

PMID:
12891226
22.

New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.

Hausheer FH, Kochat H, Parker AR, Ding D, Yao S, Hamilton SE, Petluru PN, Leverett BD, Bain SH, Saxe JD.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S3-15. Epub 2003 Jun 18. Review.

PMID:
12819940
23.

Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.

Verschraagen M, Boven E, Zegers I, Hausheer FH, Van der Vijgh WJ.

Cancer Chemother Pharmacol. 2003 Jun;51(6):525-9. Epub 2003 May 15.

PMID:
12750838
24.

The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.

Verschraagen M, Kedde MA, Hausheer FH, Van Der Vijgh WJ.

Cancer Chemother Pharmacol. 2003 Jun;51(6):499-504. Epub 2003 Apr 25.

PMID:
12715205
25.

Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.

Van Hattum AH, Schlüper HM, Hausheer FH, Pinedo HM, Boven E.

Int J Cancer. 2002 Jul 1;100(1):22-9.

26.

BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.

Boven E, Verschraagen M, Hulscher TM, Erkelens CA, Hausheer FH, Pinedo HM, van der Vijgh WJ.

Eur J Cancer. 2002 May;38(8):1148-56.

PMID:
12008205
27.

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH.

Clin Cancer Res. 2001 Apr;7(4):935-41.

28.

The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach.

Chaudhuri AR, Seetharamalu P, Schwarz PM, Hausheer FH, Ludueña RF.

J Mol Biol. 2000 Nov 10;303(5):679-92.

PMID:
11061968
29.

New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.

Van Hattum AH, Pinedo HM, Schlüper HM, Hausheer FH, Boven E.

Int J Cancer. 2000 Oct 15;88(2):260-6.

30.
31.

Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.

Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM.

Semin Oncol. 1998 Oct;25(5):584-99. Review.

PMID:
9783598
32.

Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I.

Yao S, Murali D, Seetharamulu P, Haridas K, Petluru PN, Reddy DG, Hausheer FH.

Cancer Res. 1998 Sep 1;58(17):3782-6.

33.

The partitioning of phosphoramide mustard and its aziridinium ions among alkylation and P-N bond hydrolysis reactions.

Shulman-Roskes EM, Noe DA, Gamcsik MP, Marlow AL, Hilton J, Hausheer FH, Colvin OM, Ludeman SM.

J Med Chem. 1998 Feb 12;41(4):515-29.

PMID:
9484502
35.

Ab initio quantum mechanical and X-ray crystallographic studies of gemcitabine and 2'-deoxy cytosine.

Hausheer FH, Jones ND, Seetharamulu P, Singh UC, Deeter JB, Hertel LW, Kroin JS.

Comput Chem. 1996 Aug;20(4):459-67.

PMID:
8800001
36.

Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.

Cao S, Abraham A, Nair MG, Pati R, Galivan JH, Hausheer FH, Rustum YM.

Clin Cancer Res. 1996 Apr;2(4):707-12.

37.

Binding site for ethidium cation in the major groove of B-form DNA.

Monaco RR, Hausheer FH.

J Biomol Struct Dyn. 1993 Feb;10(4):675-80.

PMID:
8466672
38.

Can oligonucleoside methylphosphonates form a stable triplet with a double DNA helix?

Hausheer FH, Singh UC, Saxe JD, Colvin OM, T'su PO.

Anticancer Drug Des. 1990 May;5(2):159-67.

PMID:
2357262
39.

Identification of local determinants of DNA interstrand crosslink formation by cyclophosphamide metabolites.

Hausheer FH, Singh UC, Saxe JD, Colvin OM.

Anticancer Drug Des. 1989 Dec;4(4):281-94.

PMID:
2619866
40.

Applications of ray tracing in molecular graphics.

Palmer TC, Hausheer FH, Saxe JD.

J Mol Graph. 1989 Sep;7(3):160-4, 157-8.

PMID:
2488855
41.

Computational analysis of structural and energetic consequences of DNA methylation.

Hausheer FH, Rao SN, Gamcsik MP, Kollman PA, Colvin OM, Saxe JD, Nelkin BD, McLennan IJ, Barnett G, Baylin SB.

Carcinogenesis. 1989 Jun;10(6):1131-7.

PMID:
2720906
42.

Intracardiac sarcoma diagnosed by left ventricular endomyocardial biopsy.

Hausheer FH, Josephson RA, Grochow LB, Weissman D, Brinker JA, Weisman HF.

Chest. 1987 Jul;92(1):177-9. No abstract available.

PMID:
3595230
43.

Diagnosis and treatment of malignant pleural effusion.

Hausheer FH, Yarbro JW.

Cancer Metastasis Rev. 1987;6(1):23-40. Review.

PMID:
2439221
44.

Reexpansion pulmonary edema.

Hausheer FH, Yarbro JW.

Mo Med. 1986 Jan;83(1):33-5. No abstract available.

PMID:
3507582
45.

Diagnosis and treatment of malignant pleural effusion.

Hausheer FH, Yarbro JW.

Semin Oncol. 1985 Mar;12(1):54-75. Review. No abstract available.

PMID:
2579439

Supplemental Content

Loading ...
Support Center